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Abstract
Background: The emergence of next-generation sequencing technology presents tremendous
opportunities to accelerate the discovery of rare variants or mutations that underlie human genetic
disorders. Although the complete sequencing of the affected individuals' genomes would be the
most powerful approach to finding such variants, the cost of such efforts make it impractical for
routine use in disease gene research. In cases where candidate genes or loci can be defined by
linkage, association, or phenotypic studies, the practical sequencing target can be made much
smaller than the whole genome, and it becomes critical to have capture methods that can be used
to purify the desired portion of the genome for shotgun short-read sequencing without biasing
allelic representation or coverage. One major approach is array-based capture which relies on the
ability to create a custom in-situ synthesized oligonucleotide microarray for use as a collection of
hybridization capture probes. This approach is being used by our group and others routinely and
we are continuing to improve its performance.
Results: Here, we provide a complete protocol optimized for large aggregate sequence intervals
and demonstrate its utility with the capture of all predicted amino acid coding sequence from 3,038
human genes using 241,700 60-mer oligonucleotides. Further, we demonstrate two techniques by
which the efficiency of the capture can be increased: by introducing a step to block cross
hybridization mediated by common adapter sequences used in sequencing library construction, and
by repeating the hybridization capture step. These improvements can boost the targeting efficiency
to the point where over 85% of the mapped sequence reads fall within 100 bases of the targeted
regions.
Conclusions: The complete protocol introduced in this paper enables researchers to perform
practical capture experiments, and includes two novel methods for increasing the targeting
efficiency. Coupled with the new massively parallel sequencing technologies, this provides a
powerful approach to identifying disease-causing genetic variants that can be localized within the
genome by traditional methods.
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Background
Sequencing capacity has greatly advanced over the years
and took a major leap with the commercialization of two
new platforms for next-generation sequencers. Currently,
three major platforms are actively being used including
Applied Biosystems (ABI) SOLiD (Sequencing by Oligo
Ligation and Detection), Illumina Genome Analyzer (GA)
and Roche 454 Sequencing System [1-3]. Further, proofs
of principle experiments with the Helicos system and
Pacific Biosciences system have been published [4-6].
These sequencer technologies differ in their sequencing
methods and hence they vary in number of reads
sequenced, read length, error characteristics. However, all
rely on the generation of shotgun libraries for sequencing.
With these technologies, a single machine can generate in
the range of 0.5-2 gigabases (Gb) of sequence reads per
day. While advancement in these technologies is certain,
the use of these technologies for sequencing targeted
regions of the genome has been limited based on the effi-
ciency of methods to enrich regions of the genome for
analysis which are matched to the capacity. The rapid
advancement in genotyping technology made possible by
the advent of DNA microarrays has resulted in a flood of
linkage and whole genome association studies for various
disorders, and now the community is overwhelmed with
genomic regions of interest for which additional targeted
sequence analysis is key bottleneck. Most recently, several
studies on exonic capture for broad based sequencing of
the amino acid coding portion of the genome have shown
successful identification of rare mutations/alleles
involved in rare genetic disorders and yielded insights in
applying the technique to searching for common variants
as well as de novo cancer mutations [7-10].
Several groups have attempted to capture regions of inter-
est by multiplex amplification [11-14]. For the target
regions, primer pairs are systematically designed and, as
the target regions are amplified by PCR, only the frag-
ments with the right primer pairs are enriched. Reports
have demonstrated successful amplification of hundreds
of ~200 bp sized fragments but with substantial bias in
the amplification between the different fragments. This
method may work well for targeting tens of genes but
beyond that scale, it requires more effort to design unique
primers and optimize the PCR amplification process to
ensure uniformity across all fragments. Also, the high cost
of primer design and amplification will not compare favo-
rably with that of sequencing as sequencing costs have
been reduced significantly. To overcome the cost and
effort of a primer design process, Porreca et al. have devel-
oped an assay that uses a microarray to design the oligo-
nucleotides in parallel [15]. Using a modification of MIP
(molecular inversion probes) assay, 55,000 exons of sizes
varying from 60 to 191 bp were targeted and although the
specificity of the capture was very good, only ~11,000
exons were captured.
At the same time when Porreca et al. published, Albert et
al. and Okou et al. described methods for using DNA
arrays to capture large genomic loci directly [15-17]. In the
following month, Hodges et al. demonstrated success at
capturing 'all' exons using the same methods with better
balance of coverage (uniformity) and specificity relative to
any other previous capture assays, and it was the least
labor intensive and the most cost-effective method [18].
However, the performance of these assays varied across
the sample types and array types used.
Albert et al. targeted a total ~5 Mb of sequences for 660
genes dispersed across the genome [16]. They reported the
specificity varied with the same array design from 38% to
76% depending on the samples captured. For their tiling
arrays encompassing from 200 Kb to 5 Mb around the
BRCA1  gene, the fraction of the reads mapped to the
intended targets varied from 14% to 64%. The Nimblegen
385 K custom array was used for all capture protocols
while the 454 GLX sequencer was used for sequencing.
Since the 454 sequencers produce longer individual reads
than those from ABI or Illumina sequencers, their
sequences are easier to map to the correct genomic loca-
tion and this should be factored in when comparing cap-
ture technologies.
Hodges et al. targeted 'all' human exons using seven Nim-
blegen arrays and sequenced the captured DNA with the
Illumina sequencer [18]. They first hybridized 500 bp
genomic fragments to all seven arrays, and the fraction of
the reads mapped to the targeted regions varied from 36%
to 55%. When they extended the definition of the targeted
region to include 300 bp upstream and downstream of
each exon, the targeting efficiency was increased to 55-
85%. Next, they used 100-200 bp fragments to hybridize
to one of the arrays in an attempt to tighten the sequenced
region around the targets. However, the specificity of the
intended targets was reduced three-fold with the exon cov-
erage rate up to 99%. For both studies, no detailed inter-
pretation was described for the specificity variations
across different array designs and sample types.
Here, we concentrate on improving the capture specificity
using consistent sample and array design. Throughout the
experiment, paired genomic DNA of both cancer and nor-
mal tissues were used from a cancer patient. We
approached with two different methods to specifically
block the adapters while generating the genomic library
for hybridization and investigated two sequential rounds
of hybridization. These changes resulted in improvements
in our measured specificity of the targeted genomic DNA
from the same sample and the same array design.BMC Genomics 2009, 10:646 http://www.biomedcentral.com/1471-2164/10/646
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Results
Baseline capture
Initial data demonstrated a specificity of the intended cap-
ture intervals of 35% with exon hit rate of 99% using 100-
200 bp genomic fragments and protocols similar to the
published results and Agilent custom 244 K oligo arrays.
These results were comparable with the Hodges et al. data
using shorter fragments (29% specificity). With these ini-
tial data as baseline, we attempted to improve the capture
efficiency by changing the hybridization protocol.
Modified capture protocol to block adapter-adapter 
hybridization
The first change we made to the Agilent hybridization pro-
tocol was to block the adapters ligated at the end of every
genomic amplicon in the hybridization mix. We assumed
that possible hybridization between different genomic
targets based on adapter-adapter hybridization will lead
to the inadvertent and non-specific enrichment of off-tar-
get fragments. This is due to the fact that all of the
genomic fragments in the hybridization mix are flanked
with the same Illumina adapters (52 nt and 34 nt), which
have comparable length to the intended genome location
specific target probes (45-60 nt). Thus, the melting tem-
perature between the adapter hybridizations will be simi-
lar to that between the appropriate genomic fragment and
its specific probe. Moreover, the effective concentration in
the hybridization of the adapter sequence is approxi-
mately 107  fold higher than the genome specific
sequences. Thus, these adapter mediated hybridization
may dominate the hybridization process.
We tried two different approaches to overcome this non-
specific pull down issue. First, to remove complementary
adapter strands from the hybridization mix, we separated
the two strands of genomic fragments and used one of the
strands for the hybridization. To accomplish this, we
biotinylated only one of the PCR primers (primer1.1)
used in the generation of the genomic library. After the
PCR step, the amplicon was bound to streptavidin beads,
and the non-biotinylated strand was collected and hybrid-
ized to the array. The second approach we tried was mech-
anistically easier to prepare than separating the two
strands. For this method, we added 10 fold molar excess
of Illumina primers to the hybridization mix assuming
that the primers will bind to all of the adapters flanking
the genomic fragments and block them from hybridizing
to other adapter sequences on different genomic frag-
ments. It was shown that both approaches increased the
specificity to ~60% with more even coverage resulting
from the simpler blocking approach, which is the pre-
ferred protocol (Table 1).
Modified capture protocol with hybridization repeat
The other protocol modification tested was to repeat the
hybridization step with the notion that each round of suc-
cessive hybridization will further enrich for the target
sequence as a substantially simplified amplicon is hybrid-
ized in the second round. In 2005, Bashiardes et al.
reported in Nature Methods on capturing genomic loci
using bacterial artificial chromosome (BAC) in solution
[19]. They performed two rounds of hybridization to
enhance targeting and achieved 50% specificity. We incor-
porated this idea and repeated the hybridization step after
the 2nd  PCR. The targeted specificity was successfully
increased up to 90% (Table 1).
This two step modified protocol was independently repli-
cated externally. Total of 2 Mb was targeted for 7,475 non-
overlapping exon intervals under 10 linkage regions
across the genome. The capture was done by Agilent cus-
tom 244 K oligo arrays strictly following the presented
protocols except for reducing the 2nd hybridization time
to 24 hrs and re-using the same capture array for the 2nd
hybridization. The 36 bp single end sequencing was per-
formed using Illumina GA I in the authors' laboratory and
the sequences were aligned to the whole genome using
MAQ (Mapping and Assembly with Qualities). With the
Table 1: Summary of the results.
Primers Single strand separation Double Hyb Specificity Exons with reads* Bases Covered*
Baseline - - - 35% 98% 75%
Single Strand - Yes - 54% 99% 92%
Primer Block Yes - - 62% (63%†)9 9 %  ( 9 9 % †)8 8 %  ( 9 4 % †)
Double Hybridization Yes - Yes 90% (82%†)9 8 %  ( 9 8 % †)8 4 %  ( 8 9 % †)
* Not considering flanking regions
† Results from replication using the tumor genomic DNA.
4 μg of genomic library was used for all experiments. The hybridization mix contained 50 μg of Human Cot-1, 52 μl of Agilent 10× Blocking agent 
and 260 μl of Agilent 2× hybridization buffer. Specificity is calculated by dividing sequence counts within the targeted region by total sequence 
counts mapable to the human genome uniquely for each run. Targeted region is defined as the targeted exon +/- 100 bp.BMC Genomics 2009, 10:646 http://www.biomedcentral.com/1471-2164/10/646
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use of blockers, the specificity resulted in 44% and by
repeating the hybridization with the blockers, the specifi-
city increased to 84%, which are comparable to the data
presented.
Analysis of the sequence data
For both the basal and modified capture protocols, only a
few percent of sequences mapped beyond 100 bp
upstream or downstream from the end oligo sequence
boundaries reflecting the sharpness of the capture which
was determined by the fragment library size initially cre-
ated (Figure 1). It has been shown in the previous reports
that SNPs (single nucleotide polymorphisms) can be reli-
ably detected [16-18]. For validation of the variant calls,
we compared the captured data to the Illumina 1 M Duo
genotyping array data of the same sample. There were
5,746 dbSNP129 SNPs that were present on both the 1 M
Duo genotyping array and within the targeted amplicons.
The amplicons were sequenced an average of 6× for single
hybridization and 9× for double hybridization. 6.3% and
9% of the polymorphic positions were not sequenced in
single and double hybridization, respectively. Excluding
Mapping of sequences relative to probe position in the genome Figure 1
Mapping of sequences relative to probe position in the genome. a) Sequence coverage distribution averaged across all 
targeted regions captured by basal capture protocol and b) sequence coverage distribution averaged across all targeted regions 
captured by double hybridization (modified) protocol show that the sequence reads are tightly limited around the targeted 
regions. Here, a targeted region is not necessarily a targeted exon but a probeset composed of multiple probes that are < 200 
bp apart to each other. The y axis plots the relative abundance and the x axis is the base position relative to the probes posi-
tions.BMC Genomics 2009, 10:646 http://www.biomedcentral.com/1471-2164/10/646
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these positions, the false negative rate (missing the variant
allele from capture data while detecting it by the Illumina
genotype data) was calculated to be 7.1% and 8.4% for
the single and double hybridization, respectively. The
false positive rate (detecting the correct variant allele
according to the HapMap Caucasian data when Illumina
genotype data calls it homozygous reference) was less
than 0.1% in both experiments. Although random sam-
pling effect was observed, the range of the variant allele
detection ratio at the polymorphic positions was nar-
rowed as the coverage increased for both experiments
(Additional file 1). In addition to base substitutions, we
have detected small (< 3 bp) insertions and deletions in
our dataset that are described in the dbSNP129. Further,
novel indels have been discovered and validated from
cancer samples that will be described more completely in
another publication.
We also gathered information about the frequency of
sequence observations and their correlation with copy
number in the targeted genome post single hybridization
based pull down. Since we used both cancer and normal
tissue samples from a single cancer patient, we compared
the copy number differences between the two (Figure 2)
based on the relative frequency of reads mapping to spe-
cific chromosomes. In this experiment, the cancer sample
was trisomic for chromosome 7 which had been previ-
ously determined by whole genome SNP typing (data not
shown). The mean number of counts normalized for the
physical length of chromosome in the tumor tissue was
1.4 relative to that in the normal tissue. Further, the cancer
sample had a loss of one chromosome, which we
observed to have 0.65 the number of reads as the same
chromosome in the normal tissue. These results indicate
the capture method in aggregate preserves the copy
number state of the original genomic DNA, and may be
useful for copy number detection even when using the
capture method. This is important for the identification of
larger deletions using sequencing based approaches. Out
of 18 places in the genome that showed regional copy
number changes in the cancer sample by whole genome
SNP typing, 6 of them harbored captured gene(s) and all
except for one place agreed between the two datasets
(Table 2). However, considering that there was no SNP
placed by Affymetrix 250 K array within the disagreed
genic region and the low resolution of the Affymetrix 250
K array for detecting copy number changes, it is likely that
the copy number changes detected by the captured
sequencing may be true. The sample was also known to
have DNA amplification of EGFR, "epidermal growth fac-
tor receptor", and a focused observation indicated ~25×
fold more reads mapping to the EGFR exons in tumor
sample than in normal sample (normalized to average
coverage of all targeted exons across the whole genome)
when single hybridization capture protocol was applied
to both samples. We note that this is substantially higher
than the SNP based copy number data which indicated a
2 fold increase at EGFR and may indicate higher dynamic
range from the capture approach followed by sequencing
than a microarray approach which has a limited dynamic
range due to fluorophor measurement. In addition, the
background noise for the ~1 Mb flanking region of EGFR
also showed the ~25× fold amplification compared to
elsewhere on the same chromosome reflecting that this 1
Mb region containing the EGFR gene is amplified itself at
the same ratio (Figure 3).
Discussion
Both Nimblegen and Agilent have released their commer-
cial products for capture. However, Nimblegen's protocol
is specific for the Roche 454 sequencer and no details of
the hybridization mix contents are provided. Agilent's
protocol uses solution based oligos and although the pro-
tocol can be adjusted for either Illumina GA or ABI SOLiD
sequencing, it is not cost effective yet for small number of
samples. Here, we described a complete instruction of the
Copy number fold differences between the normal and tumor tissues per chromosome using single hybridization capture pro- tocol with blockers Figure 2
Copy number fold differences between the normal and tumor tissues per chromosome using single hybridiza-
tion capture protocol with blockers. The cancer specimen used in these experiments was known to have a chromosome 
7 copy number gain and a chromosome 10 deletion. The normalized counts per chromosome are plotted for all chromosomes 
and are markedly different for the two chromosomes at altered copy numbers.BMC Genomics 2009, 10:646 http://www.biomedcentral.com/1471-2164/10/646
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improved capture protocol with a troubleshooting guide
(Table 3) that should facilitate the preparation of enriched
genomic libraries given access to either Agilent or Nimble-
gen hybridization equipment and any of the next genera-
tion sequencers and be applicable to other genomes.
Two simple optimizations of the hybridization protocol
have improved the capture performance significantly.
First, by blocking the adapter sequences flanking each of
the genomic fragments, we reduced the non-specific pull
down through adapter-adapter hybridization. Blocking
the nonspecific DNA is an old trick to reduce the back-
ground when microarray experiments are performed, with
human cot-1 being the most commonly used reagent to
block repetitive sequences [20]. Recently, Hodges et al.
has shown similar results with the same approach, vali-
dating our experimental protocol [21]. Secondly, we
repeated the hybridization step to further enrich the
genomic fragment pool. While the specificity was
enhanced up to 90%, this step introduced ~1% of variant
loss and some degree of bias in the relative abundance of
specific amplicons. For example, the fold difference
observed for EGFR gene was weakened by 2.5-fold when
the double hybridization capture protocol was applied,
suggesting saturation of the hybridization step effectively
normalizing the yield from each amplicon. The overall
correlation coefficient between the single hybridization
experiment and the double hybridization experiment
after excluding the ~100 exons that were outlier was 0.82.
This interferes some with the ability to reliable call copy
number state of individual exons from the pull down
sequence data. Two-round hybridization should be used
with caution when copy number detection is critical. The
array designed for our current experiments and those in
previous reports were all masked for repeats. To test
whether including the repeat regions would affect the cap-
ture, we have attempted to tile every 15 bp across a 4 Mb
region of a single chromosome using Agilent 244 K cus-
tom array without vigorously masking for the repeats. The
specificity was significantly reduced to 15~30% even with
the addition of the primer blockers and increased human
cot-1 DNA in the hybridization mix (data not shown).
EGFR DNA amplification event is preserved in sequence data Figure 3
EGFR DNA amplification event is preserved in sequence data. A 200 Kb sized moving average of the interval flanking 
a) known EGFR amplification event are plotted in genomic position and b) for reference another genomic interval around the 
FOXP2 gene also on chromosome 7 is shown demonstrating the more typical coverage. The EGFR region is amplified 25× in 
average compared to the region outside of EGFR.BMC Genomics 2009, 10:646 http://www.biomedcentral.com/1471-2164/10/646
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This phenomenon should be taken into account when it
is unavoidable to target the repeat regions.
Throughout the experiments, the sequence reads gener-
ated were tightly mapped nearby the intended probe
regions. For each probe, the local sequence coverage will
extend out in relation to the length of genomic fragment
library initially created. Without any major variations in
the genomic fragments that could interrupt the hybridiza-
tion to the probe, the sequence coverage will peak within
the probe region and decrease with increased distance.
There are ~18,000 genes in RefSeq database composed of
~33 Mb of coding sequences. To tile every 30 bp, ~914 K
probes are needed to be designed which is possible to
accomplish on a total set of four Agilent 244 K custom
arrays or one Agilent 1 M custom arrays. Figure 4 shows
the proportion of 8 million targeted bases covered at var-
ious minimum coverage for different mean coverage
within the targeted regions. For example, 76% of the tar-
geted bases were considered completely sequenced with
sequence depth of 20× or more when the mean coverage
within the targeted regions was 55×. From these data, we
can project how many sequence reads are required to
comprehensively sequence all RefSeq exons. In this
report, we used 36 bp of single end sequence reads gener-
ated by Illumina GA I. Currently, longer reads of 76 bp
paired end sequence reads can be generated and are of suf-
ficient quality for resequencing by Illumina GA IIx. This
improvement not only increases the total sequences read
by one channel of a flowcell, but also facilitates the align-
ment to the genome significantly. On average, 2.5 Gb of
sequences are generated by one channel of Illumina GA
IIx run. Of this, about half of the sequences are mapped
uniquely to the human genome and assuming 60-85%
specificity of capture, we will be able to generate 0.75-1.06
Gb of sequences within the targeted region. If targeting 33
Mb of the human genome for all RefSeq coding exons, it
will require 2 channels (quarter a machine run) of
sequencing with Illumina Genome Analyzer (GA) IIx to
achieve 20× or more coverage on ~80% of the targeted
sequences for one sample: or four samples can be
sequenced with each machine run. Alternatively, each run
of the ABI SOLiD 3 Plus instrument can generate up to 1
billion 50 base paired end reads, and a total of 40 Gb of
mapped genomic sequence, such that 12 exomes can be
resequenced at comparable coverage with each machine
run (S. Nelson, unpublished results). Thus, whole tran-
scriptome resequencing is economically feasible on the
current generation of capture tools and sequencing
devices, and, in principle, can be performed for under
$2000 per genome.
Conclusions
Capturing genomic regions for sequencing has a wide
scope of application. Many genetic studies with linkage or
association signals will benefit immensely as it becomes
possible to reliably and inexpensively capture the region
of interest and perform high throughput, shotgun
sequencing. Additionally, improvements in exonic
enrichment protocols will usher in an era of cost effective
sequencing of all the amino acid coding bases of
genomes. This will lead to more rapid identification of the
causative genes in many disorders.
Methods
Array Design
We chose to capture exonic sequence of ~3,000 cancer
genes. Two cancer gene lists, 'cancer gene census list' and
'CGP (cancer genome project) planned studies list' were
retrieved from Wellcome Trust COSMIC (catalogue of
somatic mutations in cancer) database and com-
Table 2: Genomic intervals with regional aberration detected by 
SNP array were examined by capture array and the results were 
compared.
Genomic Interval SNP array Capture array
chr1:141510591-142763403 Gain None captured
chr1:92652000-93425291 Gain Gain
chr2:42528749-43214954 Loss None captured
chr3:52074481-55997844 Gain None captured
chr6:144171325-144331154 Gain (4 copies) Gain (25 copies)
chr6:164267664-164772727 Loss Loss
chr6:169375842-169748900 Loss None captured
chr6:56774326-56953414 Loss Loss
chr7:54464822-55373694 Gain None captured
chr9:14995594-24802191 Gain None captured
chr14:68301617-68906063 Loss None captured
chr15:38336909-38504594 Gain Loss
chr16:2652029-2764985 Loss None captured
chr17:5541586-5968563 Gain No Change
chr20:39176664-39815654 Gain None captured
chr20:61246745-61325513 Gain None captured
chrX:13343420-151922021 Gain None captured
chrX:1674881-1838306 Loss None capturedBMC Genomics 2009, 10:646 http://www.biomedcentral.com/1471-2164/10/646
Page 8 of 12
(page number not for citation purposes)
bined[22]. Boundaries for exons and UTRs (untranslated
regions) were retrieved from RefSeq database and any
intervals that overlapped were merged so that non-redun-
dant contiguous intervals were generated. In total, 3,038
genes (31,678 exons) spanning 8.4 Mb were included in
the list. Based on the preliminary capture experience data
(not shown), we tiled the probes every 120 bp on average
so that the distance between the start positions of the two
consecutive probes is ~120 bp and the regions between
the probes are covered by the two flanking probes result-
ing in the same coverage as the regions within the probes.
Both forward and reverse strands of each probe region
were spotted on the array and 3 of the genes (150 exons)
of higher interest were spotted at 12× (6× for each strand).
Instead of using Nimblegen arrays as other studies have,
we used Agilent 244 K custom 60 mer arrays. Probe design
was performed using Agilent e-array system http://
www.Agilent.com with the repeat mask function on. This
resulted in losing 155 exons completely and ~27% of the
exons were partially covered (see Additional file 2).
Sample Preparation
We used a paired normal and tumor whole genomic DNA
as the starting materials. The tumor DNA was extracted
from the glioblastoma (GBM) specimen and the normal
DNA was extracted from the blood sample of the same
patient. The collections were approved by the UCLA IRB
and the samples were processed at the Biological Samples
Processing Core at UCLA using Autopure LS™ nucleic acid
purification instrument from Gentra Systems. Both the
normal and tumor samples were run on the Affymetrix
GeneChip Human Mapping 250 K array for global
genomic examination and comparison. Both chromo-
somal and regional copy number aberrations were
detected in the tumor sample with the hallmarks of gliob-
lastoma like EGFR amplification and chromosome 10 loss
observed. The detailed description of the mutational land-
scape and the chromosomal abnormalities of this cancer
sample is in preparation (Lee et al.) As we were sequenc-
ing with the Illumina Genome Analyzer, we followed the
Illumina library generation protocol version 2.3. Five μg
of high molecular weight whole genomic DNA from each
sample were diluted in 150 μl water as the starting mate-
rial. The DNA was sheared using a sonicator (Bioruptor,
Diagenode) for 1 hr at high power level to generate short
fragments. The size of the sheared product ranged
between 150 bp to 400 bp with the median size around
200-250 bp. The sample was concentrated in 30 μl of elu-
tion buffer (EB) after purification using QIAquick PCR
Purification Kit (Qiagen). To repair 3' or 5' overhangs and
Table 3: Troubleshooting Guide
Problem Possible Reason Solution
Genome is not fragmented after sonication. Buffer condition is not adaptable for sonication. Purify the DNA. We used QIAGEN PCR 
Purification Kit, eluted in EB to have it work.
Nothing is visible on the gel after 1 hr 
electrophoresis during library generation.
When the starting amount of DNA is small or 
there is significant DNA loss during the process 
for various reasons, it is possible that the DNA 
is smeared over a wide range after an hour of 
electrophoresis and not visible on the gel.
It is good to check the gel to see if the DNA is 
present after ~10 min run when the DNA is 
not smeared at a wide range.
Even though nothing is visible, it is highly 
possible that the DNA is still present. Proceed 
to the next step regardless and see if PCR 
amplifies anything.
Cannot collect ~400 ul after the stripping step. Gasket slide was re-used.
The array slide was lifted up too quickly.
Different buffer was used for the 95C stripping 
process.
Do not re-use the gasket slide.
The solution can be flushed to a collection boat 
and collected.
When using multi-array slides like 2×105 K, 
4×44 K or 8×15 K, it is still possible to run the 
capture protocol as indicated. After the 
stripping, the array slide should be slowly lifted 
up to prevent contamination. The solution 
tends to stay within the gaskets.
Not enough DNA amplified after the first 
stripping.
Stripping was not efficient. Another stripping process can be done and 
checked if there were left over genomic 
fragments hybridized on the probes. Since it 
does not matter if the stripped solution 
contains contaminants as long as the 
contaminants do not have adapters ligated at 
the end, it is possible to thoroughly continue 
the stripping process until no products get 
amplified.BMC Genomics 2009, 10:646 http://www.biomedcentral.com/1471-2164/10/646
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generate blunt ends for all the double stranded fragments,
5 μl of T4 DNA polymerase, 1 μl of Klenow DNA polymer-
ase, 5 μl of T4 PNK, 4 μl of dNTP mix, 10 μl of T4 DNA
ligase buffer with 10 mM ATP and 45 μl water were added
to the DNA solution and incubated at 20°C for 30 min
and purified to be eluted in 32 μl of EB. Single 'A' base was
added to the fragments in a reaction with 3 μl of Klenow
exo- (3' to 5' exo minus), 10 μl of dATP and 5 μl of Klenow
buffer and incubated at 37°C for 30 min. After purifica-
tion with MinElute PCR purification kit (QIAGEN) and
elution in 10 μl of EB, the Illumina supplied adapters were
ligated to the genomic fragments. Five μl of DNA ligase,
10 μl of adapter oligo mix, 25 μl of DNA ligase buffer were
used and the sample was incubated for 15 min at room
temperature. To select a size-range of templates (100-200
bp) with the correct adapter pairs ligated, the templates
were purified and size fractionated on a 2% agarose gel for
1 hr at 120 V. A band from 150-250 bases (including the
adaptors) was excised, gel extracted using Gel Extraction
Kit (Qiagen) and eluted in 30 μl of EB. The template was
PCR amplified with 1 μl of template DNA, 25 μl Phusion
DNA polymerase, 1 μl of Illumina primer 1.1, 1 μl of Illu-
mina primer 2.1 and 22 μl of water. Four replicates of PCR
reactions were performed to generate sufficient genomic
amplicon of ~4 ug for successful hybridization. Total of
18 cycles of PCR with the following cycle conditions was
performed: 30 sec at 98°C, [10 sec at 98°C, 30 sec at
65°C, 30 sec at 72°C] × 18 cycles, 5 min at 72°C and hold
at 4°C. Samples were purified, eluted in 50 μl of EB and
quantified with spectrophotometer (Nanodrop).
Percentage of targeted bases sequenced at various minimum coverage for different mean coverages Figure 4
Percentage of targeted bases sequenced at various minimum coverage for different mean coverages. X-axis 
represents the coverage per base level and the corresponding y-axis represents the percentage of targeted bases that were 
covered at greater or equal with certain coverage. Table legends describe the detail of each line shown.BMC Genomics 2009, 10:646 http://www.biomedcentral.com/1471-2164/10/646
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Capture
Hybridization
Hybridization was performed according to Agilent CGH
244 K array protocol. 4 μg of amplified products were
mixed with 50 μg of Human Cot-1 DNA (Invitrogen,
Carlsbad, CA), 52 μl of Agilent 10× Blocking Agent, 260
μl of Agilent 2× Hybridization Buffer (Agilent) and 8 μl of
each of the Illumina primer stock (100 μM each) in a final
volume of 520 μl. Blockers were designed to be comple-
mentary to the Illumina supplied primers. The sequences
provided by Illumina are shown in Table 4 (Oligonucle-
otide sequences© 2006 Illumina, Inc. All rights reserved)
and the two primers were separately ordered from IDT
(Integrated DNA technologies). The hybridization mix
was denatured at 95°C for 3 min and pre-hybridized at
37°C for 30 min. 490 μl of the prehybridized amplicons
were dispensed to a gasket slide settled in a hybridization
chamber base (Agilent), then covered with the array slide
and tightly locked with the cover chamber. Hybridization
occurred in a rotating oven (Robbins Scientific) for 65
hours at 65°C, 20 rpm.
Washing
After hybridization, the arrays were washed according to
the Agilent CGH wash procedure A protocol with the 2nd
wash extended to 5 minutes for increased stringency. The
chamber was disassembled and the array slide was sepa-
rated from the gasket slide in a glass dish filled with Oligo
aCGH wash buffer 1 (Agilent). The array slide was placed
on a slide-rack in another glass dish filled with Oligo
aCGH wash buffer 1 and washed for 5 min at room tem-
perature with stirring on a magnetic stirring plate. The
slide rack was carefully moved to a glass dish filled with
Agilent Oligo aCGH wash buffer 2 that was pre-heated to
37°C in a water bath and was washed for 5 min. After
washing, the arrays were transferred back to a glass dish
with Agilent Oligo aCGH wash buffer 1 until the next step
was ready.
Stripping
490 μl of 1× Titanium Taq PCR Buffer (Clontech) pre-
heated to 95°C was dispensed to a new gasket slide and
covered with the array slide that was washed. After
securely locking the arrays in the chamber, the array was
incubated in the 95°C rotating oven for 10 min at 20 rpm.
After this stripping process, the chamber was disassem-
bled and the array slide was carefully lifted up from one
side so that the solution converged on the gasket slide.
Pipette was used to collect the solution and transfer to a
1.5 mL microtube. This step needed to be done promptly
as the solution was heated to 95°C and it started evapo-
rating quickly. Collected solution was approximately 400
μl. The sample was aliquoted into 4 tubes so that when
added with the Illumina primer pair (final concentration
0.1 μM), enzyme (final concentration 0.5×), and dNTPs
(final concentration 250 μM each), the final volume were
100 μl. The stripped DNA was amplified by 15 cycles of
PCR as described previously. The samples were purified
with QIAquick PCR purification kit, consolidating and
eluting the sample in 50 μl of EB. The concentration of
DNA was measured and the size was checked on a 2% aga-
rose gel to confirm that the size matched the size extracted
from the gel in the previous step. Hybridization, washing
and stripping steps were repeated. The stripped DNA was
amplified under the same condition as before. After
checking the concentration and template size again, the
sample was diluted in a final concentration of 10 nM,
which is the working concentration for cluster generation.
Sequencing
The Illumina flowcell was strictly prepared according to
the manufacturer's protocol and the clusters were
sequenced on the Genome Analyzer using standard man-
ufacturer's recommended protocols. The image data pro-
duced were converted to intensity files and the sequential
image data were processed through the "Firecrest" and
"Bustard" algorithms provided by Illumina were used to
call the individual sequence reads.
Alignment
We used the Blat-like Fast Accurate Search Tool (BFAST, in
submission) to map each sequence read back to its loca-
tion in the reference genome. Here we used the NCBI
human genome build 36 as our reference genome [23].
Ten different genome indexes (Table 5) were built for use
in the BFAST alignment process to be robust to errors and
variants in the short (typically 36 base pairs) reads used
throughout this project. For each read, the potential
genome locations identified by BFAST were evaluated
using a standard local alignment algorithm and ranked by
score (see http://genome.ucla.edu/bfast). The best scoring
alignment for each read was chosen, while reads with
multiple top-scoring alignments or no alignments were
discarded. MAQ was run on the same dataset to ensure we
do not see any bias introduced by the alignment program.
The aligned reads were post filtered so that the reads with
Table 4: PCR primer sequences used to design primers for blocking the adapters in the hybridization mix.
Primer 1.1 5' AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCT
Primer 2.1 5' CAAGCAGAAGACGGCATACGAGCTCTTCCGATCT
Oligonucleotide sequences© 2006 Illumina, Inc. All rights reserved.BMC Genomics 2009, 10:646 http://www.biomedcentral.com/1471-2164/10/646
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mapping quality 0 that are aligned to multiple places in
the genome were removed. The difference of the number
of reads uniquely mapped to the whole genome (paired t-
test p-value: 0.14) and the specificities for each experi-
ment (paired t-test p-value: 0.13) were not significant
between the BFAST aligned data and MAQ aligned data
(Additional file 3). Two summary reports were created
once the most likely alignment for each read was identi-
fied by BFAST. The first report was a BED file describing
mismatches between the Illumina sequence and their cor-
responding genomic sequence. The second report was a
Wiggle (WIG) file describing sequence coverage at each
position along the chromosomes. These file formats were
used because they are compatible with the popular UCSC
genome browser. The open source SeqWare project (in
submission), which provides a LIMS tool for tracking
samples (SeqWare LIMS) and a pipeline for sequence
analysis (SeqWare Pipeline), http://seqware.source
forge.net was used throughout this work. It streamlined
the sequence processing by running the Illumina-pro-
vided image analysis and base-calling tools, BFAST, and
the report generation code, which itself is part of the
SeqWare project. The BED file was further mapped to the
dbSNP129 database to filter out known SNPs from de novo
variants.
Data Analysis
We counted the sequences that were mapped back to the
targeted region to calculate the specificity. From the WIG
file for each chromosome, the base positions that mapped
within the target intervals were filtered, and the sequence
counts for each base position were summed. The target
intervals were defined as extending 100 bp upstream and
downstream from the final oligo intended to capture each
exon interval. To compare the copy number of each chro-
mosome between the normal and tumor sample from a
patient, sequence counts were first tallied for each target
interval and divided by total sequence counts within all
target intervals for normalization. Mean of sequence
counts per chromosome was calculated and compared
between the normal and tumor sample. To compare the
background noise between flanking region of EGFR and
FOXP2 genes on chromosome 7, only the coverage in the
non-targeted region (excluding targeted region +/- 100
bp) was considered. 200 Kb moving average of the cover-
age was calculated across each region.
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